About Embryonic growth/differentiation factor 1
Embryonic growth/differentiation factor 1 (GDF1) is a protein
from Homo sapiens identified by UniProt accession
P27539, 372 residues long.
MolForge cross-references it against 0 known binders and
287 disease associations.
Target properties
| Protein name | Embryonic growth/differentiation factor 1 |
| UniProt accession | P27539 |
| Gene | GDF1 |
| Organism | Homo sapiens |
| Length | 372 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (287)
Diseases linked to this target (Open Targets).
- congenital heart defects, multiple types, 6 · score 0.75
- right atrial isomerism · score 0.74
- Tetralogy of Fallot · score 0.66
- Ivemark syndrome · score 0.60
- Congenitally uncorrected transposition of the great arteries · score 0.60
- Progressive myoclonic epilepsy · score 0.49
- conotruncal heart malformations · score 0.46
- Heterotaxia · score 0.39
- visceral heterotaxy · score 0.38
- transposition of the great arteries · score 0.33
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P27539-F1 | alphafold | PREDICTED | 73.32 | — |
Amino-acid sequence (372 residues)
MPPPQQGPCG HHLLLLLALL LPSLPLTRAP VPPGPAAALL QALGLRDEPQ GAPRLRPVPP VMWRLFRRRD PQETRSGSRR TSPGVTLQPC HVEELGVAGN IVRHIPDRGA PTRASEPASA AGHCPEWTVV FDLSAVEPAE RPSRARLELR FAAAAAAAPE GGWELSVAQA GQGAGADPGP VLLRQLVPAL GPPVRAELLG AAWARNASWP RSLRLALALR PRAPAACARL AEASLLLVTL DPRLCHPLAR PRRDAEPVLG GGPGGACRAR RLYVSFREVG WHRWVIAPRG FLANYCQGQC ALPVALSGSG GPPALNHAVL RALMHAAAPG AADLPCCVPA RLSPISVLFF DNSDNVVLRQ YEDMVVDECG CR
Explore Embryonic growth/differentiation factor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets